Arbutus Biopharma Logo
Arbutus to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 07:30 ET | Arbutus Biopharma Corporation
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Well positioned financially with a projected cash runway into the second quarter of 2024 ...
Arbutus Biopharma Logo
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
April 21, 2022 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
March 03, 2022 07:30 ET | Arbutus Biopharma Corporation
Anticipate reporting data from four clinical trials in chronically infected HBV patients in 2022 Expected to complete IND-enabling studies for two oral compounds (PD-L1 inhibitor AB-101...
Arbutus Biopharma Logo
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
February 28, 2022 06:02 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
February 17, 2022 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
January 24, 2022 07:30 ET | Arbutus Biopharma Corporation
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for...
Arbutus Biopharma Logo
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
January 04, 2022 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
December 14, 2021 07:30 ET | Arbutus Biopharma Corporation
MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has...
Arbutus Biopharma Logo
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
December 13, 2021 07:30 ET | Arbutus Biopharma Corporation
Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong...